Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Nasopharyngitis (Common Cold) - Pipeline Review, H2 2014
Publication Date Dec 2014
Product Type Report
Pages 48
Single User License help $ 2000.00
Site User License help $ 4000.00
Corporate User License help $ 6000.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Nasopharyngitis (Common Cold) - Pipeline Review, H2 2014’, provides an overview of the Nasopharyngitis (Common Cold)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Nasopharyngitis (Common Cold) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nasopharyngitis (Common Cold) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Cocrystal Pharma, Inc. Neos Therapeutics, Inc. Orbis Biosciences, Inc. Tris Pharma, Inc.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nasopharyngitis (Common Cold) Overview 7
Therapeutics Development 8
Pipeline Products for Nasopharyngitis (Common Cold) - Overview 8
Pipeline Products for Nasopharyngitis (Common Cold) - Comparative Analysis 9
Nasopharyngitis (Common Cold) - Therapeutics under Development by Companies 10
Nasopharyngitis (Common Cold) - Therapeutics under Investigation by Universities/Institutes 11
Nasopharyngitis (Common Cold) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Nasopharyngitis (Common Cold) - Products under Development by Companies 15
Nasopharyngitis (Common Cold) - Products under Investigation by Universities/Institutes 16
Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development 17
Cocrystal Pharma, Inc. 17
Neos Therapeutics, Inc. 18
Orbis Biosciences, Inc. 19
Tris Pharma, Inc. 20
Nasopharyngitis (Common Cold) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 30
(chlorpheniramine + codeine) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CCP-01 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CCP-05 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CCP-06 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CCP-07 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CCP-08 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
guaifenesin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule for Cough and Cold - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Nasopharyngitis (Common Cold) - Recent Pipeline Updates 41
Nasopharyngitis (Common Cold) - Dormant Projects 43
Nasopharyngitis (Common Cold) - Discontinued Products 44
Nasopharyngitis (Common Cold) - Product Development Milestones 45
Featured News & Press Releases 45
Sep 15, 2014: FDA accepts Tuzistra XR (CCP-01) NDA for full review 45
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 45
Feb 24, 2014: Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 45
Nov 25, 2013: Vernalis Announces Successful Pivotal Single Dose Bioavailability Study with First Cough Cold Product, CCP-01 46
Mar 06, 2013: Vernalis's First Product In Cough Cold Pipeline Achieves Proof-of-concept 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
List of Tables
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2014 8
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Nasopharyngitis (Common Cold) - Pipeline by Cocrystal Pharma, Inc., H2 2014 17
Nasopharyngitis (Common Cold) - Pipeline by Neos Therapeutics, Inc., H2 2014 18
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences, Inc., H2 2014 19
Nasopharyngitis (Common Cold) - Pipeline by Tris Pharma, Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Assessment by Combination Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Nasopharyngitis (Common Cold) Therapeutics - Recent Pipeline Updates, H2 2014 41
Nasopharyngitis (Common Cold) - Dormant Projects, H2 2014 43
Nasopharyngitis (Common Cold) - Discontinued Products, H2 2014 44

List of Figures
List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2014 8
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 24
Number of Products by Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 27
Number of Products by Top 10 Molecule Types, H2 2014 28
Number of Products by Stage and Top 10 Molecule Types, H2 2014 29

Title Date Price
2014 Opportunities in the European Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the European Cancer Diagnostics Market” is a new five-country strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next f ...Read More
Sep 2013 $19700.00
2014 Opportunities in the European Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
2014 Opportunities in the European Clinical Chemistry and Immunodiagnostics Markets” is a new five-country strategic analysis of major business opportunities emerging in the clinical chemistry a ...Read More
Sep 2013 $19700.00
2014 Opportunities in the French Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the French Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The re ...Read More
Sep 2013 $6700.00
2014 Opportunities in the French Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
“2014 Opportunities in the French Clinical Chemistry and Immunodiagnostics Markets” is a new strategic analysis of major business opportunities emerging in the French clinical chemistry an ...Read More
Sep 2013 $6100.00
2014 Opportunities in the German Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the German Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The re ...Read More
Sep 2013 $6700.00
2014 Opportunities in the German Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
“2014 Opportunities in the German Clinical Chemistry and Immunodiagnostics Markets” is a new strategic analysis of major business opportunities emerging in the German clinical chemistry an ...Read More
Sep 2013 $6100.00
2014 Opportunities in the Global Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the Global Cancer Diagnostics Market  is a new seven-country strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next ...Read More
Sep 2013 $32500.00
2014 Opportunities in the Global Clinical Chemistry
By Venture Planning Group
“2014 Opportunities in the Global Clinical Chemistry and Immunodiagnostics Markets” is a new seven-country strategic analysis of major business opportunities emerging in the clinical chemi ...Read More
Sep 2013 $33500.00
2014 Opportunities in the Italian Cancer Diagnostics Market
By Venture Planning Group
2014 Opportunities in the Italian Cancer Diagnostics Market” is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. Th ...Read More
Sep 2013 $6700.00
2014 Opportunities in the Italian Clinical Chemistry and Immunodiagnostics Markets
By Venture Planning Group
“2014 Opportunities in the Italian Clinical Chemistry and Immunodiagnostics Markets” is a new strategic analysis of major business opportunities emerging in the Italian clinical chemistry ...Read More
Sep 2013 $6100.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

  * Required field
Name *
E-mail *
Telephone 
Query 
 
   

Published By :  Global Markets Direct

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z